Venekra is a conventional drug for the treatment of acute myeloid leukemia, but taking the targeted drug Venekra in patients with acute myeloid leukemia M2a does not guarantee a certain cure.
Vinaclat belongs to the common targeted drugs, can be inhibited by BCL-2, treatment of acute myeloid leukemia M2a. But it should be noted that this kind of disease is difficult to achieve the effect of cure, often can only alleviate the condition. Secondly the dosage of Vinaclat used varies with different courses of treatment, and patients are advised to go to the hospital regularly for review and use the drug under the guidance of healthcare professionals.
Some patients may experience certain adverse reactions after using Vinaclat, such as diarrhea, nausea, anemia, fever, back pain and so on. In addition Venekra may pose a potential risk to the fetus, so pregnant women should use it with caution. For women who need to breastfeed, Vinacrine is prone to cause adverse effects on the health of the baby, so breastfeeding should be discontinued within 1 week after use.
There are many treatments for acute myeloid leukemia M2a, including medications such as cytarabine and Zoerythromycin, and Venegra is just one of them. Generally, healthcare professionals will formulate a comprehensive treatment plan according to the condition, so don’t blindly use medication for treatment.